Cantor Fitzgerald’s Pacira BioSciences PCRX Stock Holding History

Cantor Fitzgerald’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,234	Closed	-$222K	–	471
2023 Q3	$222K	Hold	7,234	–	–	0.01%	425
2023 Q2	$290K	Buy	7,234 +2,267	+46%	+$93.7K	0.01%	446
2023 Q1	$203K	Buy	+4,967	New	+$198K	﹤0.01%	535
2022 Q4	–	Sell	-5,070	Closed	-$270K	–	757
2022 Q3	$270K	Sell	5,070 -37	-0.7%	-$2.06K	0.01%	577
2022 Q2	$298K	Buy	+5,107	New	+$335K	0.01%	603

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Cantor Fitzgerald's PCRX Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 7,234 shares — an estimated $222K sold.

Cantor Fitzgerald first reported a position in PCRX in Q2 2022 and held it in 5 quarters. The position peaked at $298K in Q2 2022. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

Cantor Fitzgerald reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
Cantor Fitzgerald sold 7,234 Pacira BioSciences shares in Q4 2023, an estimated $222K.
Cantor Fitzgerald first reported a position in Pacira BioSciences in Q2 2022 and held it in 5 quarters.
Cantor Fitzgerald's Pacira BioSciences position peaked at $298K in Q2 2022.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.